NS
Natarajan Sethuraman (President, Research & Develop.) filed 1 Form 4 report in the trailing twelve months (0 purchases, 1 sale), most often in Entrada Therapeutics, Inc. (TRDA). The largest single filing was $399K of TRDA (25,907 sh × $15.39, as filed), executed May 4. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
1
0 buys · 1 sells
Median delay
–
measured on stock purchases
Volume, ttmiDollar value disclosed in the trailing twelve months
$399K
shares × price, as filed
Last traded
May 4
Filed May 4
Median ADV $2.8M across their filed names
Open performance→Volume by month
Buys $0
Sells $635K
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
1 filing
Sector per market data · by filing · past 12 months
Most traded names
TRDARecent filings
TRDASALE
Entrada Therapeutics, Inc.
View filing →
$399K25,907 sh × $15.39
Exec May 4
Filed May 4 · 5:30 PM ET TRDASALE Entrada Therapeutics, Inc. View filing → $236K
11,703 sh × $20.15
Exec Dec 3 2024
Filed Dec 3 2024 · 5:30 PM ET TRDASALE Entrada Therapeutics, Inc. View filing → $179K
9,554 sh × $18.71
Exec Nov 6 2024
Filed Nov 6 2024 · 5:30 PM ET